Open Access

LY294002 inhibits the Warburg effect in gastric cancer cells by downregulating pyruvate kinase M2

  • Authors:
    • Jian Lu
    • Min Chen
    • Sumeng Gao
    • Jigang Yuan
    • Zhu Zhu
    • Xiaoping Zou
  • View Affiliations

  • Published online on: January 23, 2018     https://doi.org/10.3892/ol.2018.7843
  • Pages: 4358-4364
  • Copyright: © Lu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

The ‘Warburg effect’ is considered a vital hallmark of cancer cells, characterized by an altered metabolism, in which cells rely on aerobic glycolysis. As a key enzyme of aerobic glycolysis, pyruvate kinase M2 (PKM2) serves a crucial role in tumorigenesis. Accumulating studies have indicated that PKM2 is a potential target for cancer therapy. The aim of the present study was to assess the anticancer effects of LY294002, a specific phosphatidylinositol‑3‑kinase inhibitor, on gastric cancer (GC) cells and further explore its possible mechanism in vitro. The present study revealed that LY294002 inhibited GC cell proliferation, induced early apoptosis and significantly decreased lactate dehydrogenase activity and lactate production, in part through inhibiting PKM2 expression. In summary, LY294002 exhibits anticancer effects on GC, partly via the downregulation of PKM2.

References

1 

Wadhwa R, Song S, Lee JS, Yao Y, Wei Q and Ajani JA: Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol. 10:643–655. 2013. View Article : Google Scholar : PubMed/NCBI

2 

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI

3 

Masoudi-Nejad A and Asgari Y: Metabolic cancer biology: Structural-based analysis of cancer as a metabolic disease, new sights and opportunities for disease treatment. Semin Cancer Biol. 30:21–29. 2015. View Article : Google Scholar : PubMed/NCBI

4 

Pavlova NN and Thompson CB: The emerging hallmarks of cancer metabolism. Cell Metab. 23:27–47. 2016. View Article : Google Scholar : PubMed/NCBI

5 

Shen CT, Wei WJ, Qiu ZL, Song HJ and Luo QY: Afamin promotes glucose metabolism in papillary thyroid carcinoma. Mol Cell Endocrinol. 434:108–115. 2016. View Article : Google Scholar : PubMed/NCBI

6 

Jan CI, Tsai MH, Chiu CF, Huang YP, Liu CJ and Chang NW: Fenofibrate suppresses oral tumorigenesis via reprogramming metabolic processes: Potential drug repurposing for oral cancer. Int J Biol Sci. 12:786–798. 2016. View Article : Google Scholar : PubMed/NCBI

7 

Navarro P, Bueno MJ, Zagorac I, Mondejar T, Sanchez J, Mourón S, Muñoz J, Gómez-López G, Jimenez-Renard V, Mulero F, et al: Targeting tumor mitochondrial metabolism overcomes resistance to antiangiogenics. Cell Rep. 15:2705–2718. 2016. View Article : Google Scholar : PubMed/NCBI

8 

Li Z, Yang P and Li Z: The multifaceted regulation and functions of PKM2 in tumor progression. Biochim Biophys Acta. 1846:285–296. 2014.PubMed/NCBI

9 

Jurica MS, Mesecar A, Heath PJ, Shi W, Nowak T and Stoddard BL: The allosteric regulation of pyruvate kinase by fructose-1,6-bisphosphate. Structure. 6:195–210. 1998. View Article : Google Scholar : PubMed/NCBI

10 

Tamada M, Suematsu M and Saya H: Pyruvate kinase M2: Multiple faces for conferring benefits on cancer cells. Clin Cancer Res. 18:5554–5561. 2012. View Article : Google Scholar : PubMed/NCBI

11 

Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL and Cantley LC: The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 452:230–233. 2008. View Article : Google Scholar : PubMed/NCBI

12 

Christofk HR, Vander Heiden MG, Wu N, Asara JM and Cantley LC: Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature. 452:181–186. 2008. View Article : Google Scholar : PubMed/NCBI

13 

Liu WR, Tian MX, Yang LX, Lin YL, Jin L, Ding ZB, Shen YH, Peng YF, Gao DM, Zhou J, et al: PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma. Oncotarget. 6:846–861. 2015.PubMed/NCBI

14 

Mukherjee J, Ohba S, See WL, Phillips JJ, Molinaro AM and Pieper RO: PKM2 uses control of HuR localization to regulate p27 and cell cycle progression in human glioblastoma cells. Int J Cancer. 139:99–111. 2016. View Article : Google Scholar : PubMed/NCBI

15 

Wong N, Yan J, Ojo D, De Melo J, Cutz JC and Tang D: Changes in PKM2 associate with prostate cancer progression. Cancer Invest. 32:330–338. 2014. View Article : Google Scholar : PubMed/NCBI

16 

Shashni B, Sakharkar KR, Nagasaki Y and Sakharkar MK: Glycolytic enzymes PGK1 and PKM2 as novel transcriptional targets of PPARγ in breast cancer pathophysiology. J Drug Target. 21:161–174. 2013. View Article : Google Scholar : PubMed/NCBI

17 

Yu G, Yu W, Jin G, Xu D, Chen Y, Xia T, Yu A, Fang W, Zhang X, Li Z and Xie K: PKM2 regulates neural invasion of and predicts poor prognosis for human hilar cholangiocarcinoma. Mol Cancer. 14:1932015. View Article : Google Scholar : PubMed/NCBI

18 

Chen G, Feng W, Zhang S, Bian K, Yang Y, Fang C, Chen M, Yang J and Zou X: Metformin inhibits gastric cancer via the inhibition of HIF1α/PKM2 signaling. Am J Cancer Res. 5:1423–1434. 2015.PubMed/NCBI

19 

Gao Y, Xu D, Yu G and Liang J: Overexpression of metabolic markers HK1 and PKM2 contributes to lymphatic metastasis and adverse prognosis in Chinese gastric cancer. Int J Clin Exp Pathol. 8:9264–9271. 2015.PubMed/NCBI

20 

Tang R, Yang C, Ma X, Wang Y, Luo D, Huang C, Xu Z, Liu P and Yang L: MiR-let-7a inhibits cell proliferation, migration, and invasion by down-regulating PKM2 in gastric cancer. Oncotarget. 7:5972–5984. 2016.PubMed/NCBI

21 

Luo W and Semenza GL: Emerging roles of PKM2 in cell metabolism and cancer progression. Trends Endocrinol Metab. 23:560–566. 2012. View Article : Google Scholar : PubMed/NCBI

22 

Panasyuk G, Espeillac C, Chauvin C, Pradelli LA, Horie Y, Suzuki A, Annicotte JS, Fajas L, Foretz M, Verdeguer F, et al: PPARγ contributes to PKM2 and HK2 expression in fatty liver. Nat Commun. 3:6722012. View Article : Google Scholar : PubMed/NCBI

23 

Chen L, Shi Y, Liu S, Cao Y, Wang X and Tao Y: PKM2: The thread linking energy metabolism reprogramming with epigenetics in cancer. Int J Mol Sci. 15:11435–11445. 2014. View Article : Google Scholar : PubMed/NCBI

24 

Shuch B, Linehan WM and Srinivasan R: Aerobic glycolysis: A novel target in kidney cancer. Expert Rev Anticancer Ther. 13:711–719. 2013. View Article : Google Scholar : PubMed/NCBI

25 

Sun Q, Chen X, Ma J, Peng H, Wang F, Zha X, Wang Y, Jing Y, Yang H, Chen R, et al: Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci USA. 108:pp. 4129–4134. 2011; View Article : Google Scholar : PubMed/NCBI

26 

García-Carracedo D, Villaronga MÁ, Álvarez-Teijeiro S, Hermida-Prado F, Santamaría I, Allonca E, Suárez-Fernández L, Gonzalez MV, Balbín M, Astudillo A, et al: Impact of PI3K/AKT/mTOR pathway activation on the prognosis of patients with head and neck squamous cell carcinomas. Oncotarget. 7:29780–29793. 2016. View Article : Google Scholar : PubMed/NCBI

27 

Chen S, Fisher RC, Signs S, Molina LA, Shenoy AK, Lopez MC, Baker HV, Koomen JM, Chen Y, Gittleman H, et al: Inhibition of PI3K/Akt/mTOR signaling in PI3KR2-overexpressing colon cancer stem cells reduces tumor growth due to apoptosis. Oncotarget. 8:50476–50488. 2016.PubMed/NCBI

28 

Petrov A, Beer M and Blome S: Development and validation of a harmonized TaqMan-based triplex real-time RT-PCR protocol for the quantitative detection of normalized gene expression profiles of seven porcine cytokines. PLoS One. 9:e1089102014. View Article : Google Scholar : PubMed/NCBI

29 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

30 

Bauer TM, Patel MR and Infante JR: Targeting P13Kinase in cancer. Pharmacol Ther. 146:53–60. 2015. View Article : Google Scholar : PubMed/NCBI

31 

Ying J, Xu Q, Liu B, Zhang G, Chen L and Pan H: The expression of the PI3K/AKT/mTOR pathway in gastric cancer and its role in gastric cancer prognosis. Onco Targets Ther. 8:2427–2433. 2015. View Article : Google Scholar : PubMed/NCBI

32 

Zhu L, Derijard B, Chakrabandhu K, Wang BS, Chen HZ and Hueber AO: Synergism of PI3K/Akt inhibition and Fas activation on colon cancer cell death. Cancer Lett. 354:355–364. 2014. View Article : Google Scholar : PubMed/NCBI

33 

Denoyelle C, Lambert B, Meryet-Figuière M, Vigneron N, Brotin E, Lecerf C, Abeilard E, Giffard F, Louis MH, Gauduchon P, et al: miR-491-5p-induced apoptosis in ovarian carcinoma depends on the direct inhibition of both BCL-XL and EGFR leading to BIM activation. Cell Death Dis. 5:e14452014. View Article : Google Scholar : PubMed/NCBI

34 

Houédé N and Pourquier P: Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: Its potential use in the treatment of bladder cancers. Pharmacol Ther. 145:1–18. 2015. View Article : Google Scholar : PubMed/NCBI

35 

Wang L, Wu J, Lu J, Ma R, Sun D and Tang J: Regulation of the cell cycle and PI3K/Akt/mTOR signaling pathway by tanshinone I in human breast cancer cell lines. Mol Med Rep. 11:931–939. 2015. View Article : Google Scholar : PubMed/NCBI

36 

Li Y, Zhang Z, Zhang X, Lin Y, Luo T, Xiao Z and Zhou Q: A dual PI3K/AKT/mTOR signaling inhibitor miR-99a suppresses endometrial carcinoma. Am J Transl Res. 8:719–731. 2016.PubMed/NCBI

37 

Su CC and Chiu TL: Tanshinone IIA decreases the protein expression of EGFR and IGFR blocking the PI3K/Akt/mTOR pathway in gastric carcinoma AGS cells both in vitro and in vivo. Oncol Rep. 36:1173–1179. 2016. View Article : Google Scholar : PubMed/NCBI

38 

Riquelme I, Tapia O, Espinoza JA, Leal P, Buchegger K, Sandoval A, Bizama C, Araya JC, Peek RM and Roa JC: The gene expression status of the PI3K/AKT/mTOR pathway in gastric cancer tissues and cell lines. Pathol Oncol Res. 22:797–805. 2016. View Article : Google Scholar : PubMed/NCBI

39 

Yu L, Chen X, Wang L and Chen S: The sweet trap in tumors: Aerobic glycolysis and potential targets for therapy. Oncotarget. 7:38908–38926. 2016.PubMed/NCBI

40 

Chu B, Wang J, Wang Y and Yang G: Knockdown of PKM2 induces apoptosis and autophagy in human A549 alveolar adenocarcinoma cells. Mol Med Rep. 12:4358–4363. 2015. View Article : Google Scholar : PubMed/NCBI

41 

Sun H, Zhu A, Zhang L, Zhang J, Zhong Z and Wang F: Knockdown of PKM2 suppresses tumor growth and invasion in lung adenocarcinoma. Int J Mol Sci. 16:24574–24587. 2015. View Article : Google Scholar : PubMed/NCBI

42 

He Y, Wang Y, Liu H, Xu X, He S, Tang J, Huang Y, Miao X, Wu Y, Wang Q and Cheng C: Pyruvate kinase isoform M2 (PKM2). participates in multiple myeloma cell proliferation, adhesion and chemoresistance. Leuk Res. 39:1428–1436. 2015.

43 

Liu Q, Liang M, Liu T, Vuitton L, Zheng S, Gao X, Lu M, Li X, Sheyhidin I and Lu X: M2 isoform of pyruvate kinase (PKM2) is upregulated in Kazakh's ESCC and promotes proliferation and migration of ESCC cells. Tumour Biol. 37:2665–2672. 2016. View Article : Google Scholar : PubMed/NCBI

44 

Mohammad GH, Olde Damink SW, Malago M, Dhar DK and Pereira SP: Pyruvate kinase M2 and lactate dehydrogenase a are overexpressed in pancreatic cancer and correlate with poor outcome. PLoS One. 11:e01516352016. View Article : Google Scholar : PubMed/NCBI

45 

Lu W, Cao Y, Zhang Y, Li S, Gao J, Wang XA, Mu J, Hu YP, Jiang L, Dong P, et al: Up-regulation of PKM2 promote malignancy and related to adverse prognostic risk factor in human gallbladder cancer. Sci Rep. 6:263512016. View Article : Google Scholar : PubMed/NCBI

46 

Nemazanyy I, Espeillac C, Pende M and Panasyuk G: Role of PI3K, mTOR and Akt2 signalling in hepatic tumorigenesis via the control of PKM2 expression. Biochem Soc Trans. 41:917–922. 2013. View Article : Google Scholar : PubMed/NCBI

47 

Yang L, Hou Y, Yuan J, Tang S, Zhang H, Zhu Q, Du YE, Zhou M, Wen S, Xu L, et al: Twist promotes reprogramming of glucose metabolism in breast cancer cells through PI3K/AKT and p53 signaling pathways. Oncotarget. 6:25755–25769. 2015.PubMed/NCBI

Related Articles

Journal Cover

April 2018
Volume 15 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Lu, J., Chen, M., Gao, S., Yuan, J., Zhu, Z., & Zou, X. (2018). LY294002 inhibits the Warburg effect in gastric cancer cells by downregulating pyruvate kinase M2. Oncology Letters, 15, 4358-4364. https://doi.org/10.3892/ol.2018.7843
MLA
Lu, J., Chen, M., Gao, S., Yuan, J., Zhu, Z., Zou, X."LY294002 inhibits the Warburg effect in gastric cancer cells by downregulating pyruvate kinase M2". Oncology Letters 15.4 (2018): 4358-4364.
Chicago
Lu, J., Chen, M., Gao, S., Yuan, J., Zhu, Z., Zou, X."LY294002 inhibits the Warburg effect in gastric cancer cells by downregulating pyruvate kinase M2". Oncology Letters 15, no. 4 (2018): 4358-4364. https://doi.org/10.3892/ol.2018.7843